Banking fat and using adipose-derived products sit at a crossroads of biology, law, and ethics that most marketing materials do not explain. Patients are not just storing tissue when they sign a banking agreement. They are entering a legal relationship that defines who owns the stored material, what it can be used for, whether commercial products can be developed from it, and what rights they retain if things change. Regulators, professional medical ethics codes, and state legislatures have all started paying closer attention to this landscape, and patients have more at stake in understanding it than they are usually told.
TLDR: Banking adipose tissue and receiving stem cell therapies involve legal and ethical decisions alongside medical ones. Ethical guidance and legal frameworks require clear informed consent, disclosure of any commercial uses of tissue, and honest explanation of a therapy’s FDA status. Adipose tissue is classified by the FDA as a structural tissue, which means that many products derived from enzymatic or aggressive processing of fat are treated as drugs requiring formal regulatory pathways, not simple tissue transfers. State laws like Florida’s 2025 SB 1768 add informed consent and advertising requirements specific to their jurisdiction.
Important Disclaimer: Save My Fat does not provide legal advice and cannot interpret individual contracts or agreements for patients. No adipose-derived stem cell product is FDA-approved as a treatment for any disease unless explicitly reflected in FDA labeling. This article summarizes publicly available ethics, regulatory, and legal sources for educational purposes only and does not constitute legal or medical advice. Patients should consult their own lawyers and licensed clinicians before signing any tissue banking or stem cell therapy agreement.
A clinic advertisement reads: “Own your own stem cells for life” or “Stem cell freedom: your biology, your choice.” For many patients, that language sounds like straightforward empowerment. But behind it is a set of legal questions that the marketing never addresses. Who actually owns tissue once it is handed to a bank? What can the bank or the physician do with it? If commercial products are developed from your cells, do you share in the proceeds? And what does it mean, legally, when a therapy is described as “your own” if the FDA considers the process that created it to be drug manufacturing?
Most banking and stem cell marketing emphasizes possibility: the promise of future options, the preservation of younger cells, the reassurance that you are taking control. What it rarely explains is the contract you are signing, the regulatory classification of the product you may later receive, or the gap between state-level authorization and federal oversight. Informed patients ask different questions than patients who have only read the brochure.
This guide covers who owns banked tissue and what ethical and legal standards say about commercial use, what informed consent requirements look like for banking and for clinical therapies, how the FDA classifies adipose tissue and the products derived from it, what Expanded Access actually is and how it differs from clinical trials and commercial offerings, how Florida’s 2025 stem cell law works as a case study in state-level regulation, and what questions every patient should be asking before they sign anything.
Who Owns Banked Adipose Tissue and Future Products?
Biobank Ethics and the Foundation of Ownership
The ethical literature on tissue banking establishes informed consent as the foundational requirement for any use of donated or banked biological material. A peer-reviewed analysis of the ethical, legal, and practical considerations for adipose stem cell banks, accessible at PubMed, describes how research tissue banks must secure ethical approval, establish governance structures defining how samples are used and shared, and provide donors with transparent information about the potential uses of their biological material, including whether tissue or products from it could be commercialized.
A 2012 review of ethical and legal considerations regarding ownership and use of human biological materials, accessible at PMC3440234, synthesizes the legal landscape more broadly. It notes that property rights in separated biological material are not clearly resolved under U.S. law in all scenarios, and that courts have in some cases held that individuals do not retain property rights in excised tissue. At the same time, ethical frameworks and many legal requirements insist that this does not mean that biological materials can be used in any way the holder sees fit. The ethical principle is that use, particularly commercial use, requires the donor’s informed consent.
AMA Ethics and Commercial Use
The AMA Code of Medical Ethics opinion on commercial use of human biological materials addresses this directly. It states that physicians should not use human biological materials for commercial purposes without the patient’s knowledge and consent. The AMA guidance specifies that when patients are asked to provide biological materials for purposes that may generate commercial products, they should be informed of that potential and given the opportunity to consent or decline. It also acknowledges that patients generally do not have automatic rights to share in commercial profits from products developed from their materials unless such an arrangement is explicitly part of an agreement, but it emphasizes that the absence of a profit-sharing right does not eliminate the disclosure obligation.
What This Means for Adipose Tissue Banking Contracts
For personal-use tissue banks like Save My Fat, where the primary purpose is preserving tissue for the donor’s own potential future use, the central consent questions differ somewhat from research tissue banks. The key terms patients should look for include a clear statement that the tissue is the patient’s property and the facility is acting as custodian, specification of what the bank can and cannot do with the tissue beyond storage (including whether it can be used for research, process optimization, or product development), what happens to ownership rights in the event that products are developed from the stored material, and what the patient’s options are if the bank ceases operations, changes ownership, or is acquired.
The complete guide to adipose tissue banking covers what the banking process involves from collection through long-term storage, and the how banking works article explains the step-by-step mechanics. Patients reviewing any banking agreement should ensure the contract reflects the same principles the marketing describes.
Informed Consent: What Needs to Be in Writing
Core Elements for Tissue Banking Consent
Health law commentary on tissue banking identifies several categories of information that consent documents should clearly contain. Patients should understand what tissue is being collected and how it will be processed and stored. They should know whether the tissue is reserved for their possible future clinical use, for research, or for both, and whether that can change over time. They should understand whether they retain any rights to the tissue itself, to data derived from it, or to commercial products developed from it. They should be told how long the tissue will be stored, what happens if fees lapse or if the bank ceases operations, and whether they can withdraw consent, request destruction of the tissue, or request its transfer to another facility, and under what conditions.
What makes a consent document genuinely useful is not just that it covers these topics, but that it covers them specifically enough that a patient can understand what they agreed to years after signing. Vague language about “potential future uses” without defining what those uses are provides limited protection and limited understanding.
Consent for Clinical Therapies
When the use at issue is a clinical therapy rather than storage, the consent requirements shift toward the clinical domain. For investigational therapies, meaning those that are not FDA-approved and are being studied in clinical trials, FDA and IRB (Institutional Review Board, the independent ethics oversight body required for research involving human participants) requirements specify that consent must clearly disclose the investigational status of the therapy, describe known and unknown risks as specifically as possible, explain what alternatives exist including standard of care and no treatment, and confirm that participation is voluntary and can be stopped at any time without penalty or effect on other care.
For context on what the clinical trial process involves and what enrollment in a research study actually looks like, the guide to clinical trials for regenerative medicine walks through the key elements.
Florida SB 1768 and Consent for Unapproved Therapies
Florida’s 2025 stem cell therapy law, formally designated CS/CS/SB 1768 and accessible at flsenate.gov, addresses consent for a specific category: stem cell therapies offered by licensed Florida physicians that are not FDA-approved. Under SB 1768, physicians offering such therapies are required to obtain a signed consent form before performing the procedure. That consent must specifically inform the patient that the therapy is not FDA-approved and explain that anticipated results cannot be guaranteed. The consent must describe the recognized risks and complications associated with the specific therapy, the potential benefits the physician believes may result, and the alternatives to the therapy, including the option of no treatment. Physicians must also encourage patients to consult their primary care provider before proceeding.
The law further requires that any advertising for stem cell therapies include a clearly visible notice that the therapy is not FDA-approved. Violations of the consent and advertising requirements carry professional discipline consequences, and the use of cells or tissues derived from fetuses or embryos after abortion is prohibited under the law, with criminal penalties for violations. The Florida Senate bill summary provides additional context on the scope and intent of the legislation.
How the FDA Treats Adipose Tissue and Adipose-Derived Products
Structural Tissue Classification
The FDA’s approach to regulating human cell and tissue products (HCT/Ps, which stands for human cells, tissues, and cellular and tissue-based products) classifies them based on two primary criteria: whether they are minimally manipulated, and whether they are intended for homologous use. The FDA’s guidance on minimal manipulation and homologous use explains how these criteria apply to different tissue types, including adipose tissue.
For structural tissues, of which adipose is considered one, minimal manipulation means processing that does not alter the original relevant characteristics of the tissue that relate to its utility as structural tissue. Adipose tissue’s recognized structural functions are cushioning, support, and energy storage. Processing steps like rinsing, centrifugation, and cryopreservation of intact tissue may qualify as minimal manipulation because they preserve these structural characteristics. Enzymatic digestion that breaks apart the tissue’s cellular architecture, separating cells from the extracellular matrix and removing the adipocyte-majority composition, crosses the line into more than minimal manipulation because it fundamentally changes what the tissue is.
Why Enzymatic SVF Processing Often Changes the Regulatory Category
Stromal vascular fraction (SVF), which is the concentrated cellular mixture obtained by enzymatically digesting adipose lipoaspirate, is a specific focus of FDA guidance. The FDA’s position, reflected in enforcement actions and court decisions including three federal circuit court rulings between 2014 and 2024 that upheld FDA authority over processed adipose products, is that enzymatic digestion is more than minimal manipulation for structural tissue.
This matters practically because a product that is more than minimally manipulated, or that is intended for non-homologous use, falls outside the relatively lighter regulatory framework of 21 CFR Part 1271 and into the full drug and biologic approval pathway. It requires an Investigational New Drug (IND) application for clinical investigation and a Biologics License Application (BLA) for marketing. Professional analyses, including commentary from pain medicine societies on the implications of the FDA’s minimal manipulation and homologous use guidance accessible at asra.com, confirm this reading and its practical implications for clinicians offering these services.
What Non-Homologous Use Means for Fat-Based Therapies
Homologous use means using the tissue to perform the same basic function in the recipient that it performed in the donor. Adipose tissue’s recognized functions are structural: cushioning, support, and energy storage. Using adipose-derived cells to attempt to regenerate cartilage or tendon, treat a systemic immune condition, or address a neurological disease is generally considered non-homologous use, because those are not the basic functions that adipose tissue performs in its native context.
When patients see advertisements for “fat stem cell injections” that promise to rebuild cartilage, reverse autoimmune disease, or regenerate organ function, those claims typically describe non-homologous uses of products that the FDA would consider biologics requiring formal approval pathways. Whether an offer actually complies with FDA regulations depends on the specific product, the processing used, the claimed indication, and whether an IND is in place.
Expanded Access, Compassionate Use, and Reagan-Udall
What FDA Expanded Access Actually Is
Expanded Access, also called compassionate use, is a specific regulatory pathway that allows patients with serious or life-threatening conditions to access investigational medical products outside of clinical trials when no satisfactory alternative exists. The FDA’s Expanded Access page describes the three main forms: individual patient Expanded Access (for single patients in urgent situations), intermediate-size population Expanded Access (for groups of patients with the same condition), and treatment Investigational New Drug (for wider availability while a product is in late development).
A 2017 review of FDA’s Expanded Access Program accessible at PMC5443564 explains the process in more detail. For a patient to access a product through Expanded Access, the manufacturer must agree to provide the product, the treating physician must submit an application to the FDA (which has different requirements depending on the form of access), and the FDA must authorize the use. Expanded Access is not a shortcut around clinical trials. It is a specific pathway designed for patients who cannot access clinical trials and for whom the potential benefit justifies the risk given their condition.
Reagan-Udall Expanded Access Navigator
The Reagan-Udall Foundation’s Expanded Access Navigator is a free public resource designed to help patients, physicians, and family members understand and navigate the Expanded Access process. It provides educational materials about what Expanded Access involves, what it requires from patients and physicians, and what limitations it has. It also hosts a directory where manufacturers can post their Expanded Access policies, including specific programs they have established for investigational products.
An example of how this works in practice: a company with an autologous adipose-derived MSC product for knee osteoarthritis might list an Expanded Access program on the Navigator, describing the eligibility criteria, the consent requirements specific to that program, and the follow-up structure. A patient or physician who finds this listing can see that it represents a formal program with defined parameters and manufacturer involvement, rather than a commercial offering with no regulatory documentation.
The Difference Between Expanded Access and Commercial “Stem Cell” Services
The operational distinctions between Expanded Access and commercial stem cell offers are significant. Legitimate Expanded Access programs have an IND number or protocol documentation that can be verified, involve manufacturer participation and FDA authorization, and include monitoring and adverse event reporting. Commercial stem cell services that use Expanded Access language without meeting these criteria are misrepresenting their regulatory status. The how to spot unethical stem cell clinics guide on this site provides a practical framework for identifying red flags in this space.
State Stem Cell Laws: Florida’s SB 1768 as a Case Study
What the Florida Law Does and Requires
Florida’s SB 1768, effective in 2025, is notable as one of the more detailed state-level efforts to regulate stem cell therapy without simply prohibiting it. The law authorizes Florida-licensed physicians to offer certain stem cell therapies that are not FDA-approved, subject to specific professional obligations. These include the informed consent requirements described earlier, advertising disclosure requirements, and the prohibition on therapies using cells derived from aborted fetuses or embryos.
The law creates a defined professional context in which unapproved stem cell therapies can be offered with physician accountability. It does not create an exemption from federal drug and biologic laws. A physician offering enzymatically processed SVF for a non-homologous use in Florida, for example, would still need to comply with federal HCT/P and biologic regulations regardless of what the state law permits at the professional conduct level. State law governs professional licensing and discipline; it does not override the FDA’s product classification authority.
The Relationship Between State and Federal Authority
This distinction is important and worth stating directly. State laws about stem cell therapy determine what a state-licensed physician is permitted to do under state professional licensing standards and what disclosures they are required to make. They do not change how the FDA classifies a product, what clinical evidence the FDA requires for approval, or what federal regulations govern manufacturing and distribution. A product that is classified as an unapproved biologic drug under federal law does not become something different because a state law permits physicians to offer it in certain circumstances.
Patients in states with “stem cell freedom” laws should understand that compliance with state law is a necessary but not sufficient condition for legitimate therapy. The additional question is always whether the product being offered is being handled in compliance with applicable federal regulations, including whether it is being studied under an appropriate IND.
Questions Florida Patients Should Still Ask
Even with SB 1768’s consent requirements in place, patients in Florida should ask their physician whether the therapy is being offered under an IND, IRB review, or clinical trial registration, how product quality and safety are ensured, whether this specific product has been studied in published peer-reviewed research, and what the physician would recommend if they decided not to proceed. The emerging research page on this site tracks where legitimate research in adipose-derived cell therapies is currently active and can help patients evaluate what they are being offered against the actual research landscape.
Practical Questions to Ask Before Banking or Treatment
Contract Questions for Tissue Banking
Before signing a banking agreement, patients should be able to answer the following questions from the contract itself. Who legally owns the tissue once it is in storage? Can the bank or any affiliated party use the tissue or data from it for research, process development, or commercial product creation, and if so, under what conditions and with what notification? Does the patient retain any rights to profits if commercial products are developed from their tissue? What happens to the tissue if the patient stops paying storage fees, dies, or is incapacitated? What happens if the bank is acquired by another company, merges, or closes? How can the patient request destruction, return, or transfer of their tissue, and what are the timelines and procedures?
These are not adversarial questions. They are the basic terms that any informed, consenting adult should understand before entering a long-term custodial relationship with their own biological material.
Questions for Any Clinical Use of Adipose-Derived Products
Before agreeing to any clinical use of adipose-derived cells or products, patients should ask: Is this product minimally manipulated and homologously used, or has it been classified as a drug or biologic requiring an IND? Is there an IND number, IRB approval, or ClinicalTrials.gov registration for this specific protocol? Is this being offered as part of a registered clinical trial, through an Expanded Access program, or as a purely commercial service? What are the known risks, and how were they characterized? What written consent will I receive and how much time do I have to review it?
The patient’s guide to adipose-derived stem cells provides background on the biology, and the information on providers and pricing explains how Save My Fat’s banking service is structured.
Red Flags Worth Recognizing
Marketing that guarantees cure or describes a therapy as “risk-free” is making claims that neither the FDA nor basic principles of medical ethics support for any investigational therapy. The absence of clear disclosure that a product is not FDA-approved, whether in advertising or in a consent document, is a warning sign. Consent forms that are presented as a quick signature rather than as documents with time to review and ask questions are not meeting the spirit of what informed consent requires. Claims that patients “own” their cells and can “withdraw and profit at any time” that are not reflected in specific contractual terms should prompt careful reading of what the contract actually says.
Frequently Asked Questions
If I bank my fat, do I own any treatments made from it in the future?
The short answer depends entirely on what your banking agreement says, not on assumptions about what banking implies. Ethical frameworks and legal guidance establish that commercial use of biological materials requires informed consent, but they do not automatically grant donors ownership of downstream products. Your contract may specify that you retain access rights to your stored tissue for defined purposes while the bank holds it as custodian, without giving you ownership of any products derived from it if further processing occurs. Reading the specific ownership, use, and commercialization provisions of your agreement before signing is essential. This article summarizes general principles; it is not legal advice applicable to any specific contract.
Can a company or doctor patent or profit from products made from my cells without telling me?
Ethical guidance from the AMA says no, not without appropriate disclosure and consent. The AMA Code of Medical Ethics opinion on commercial use states that physicians should not use patients’ biological materials for commercial purposes without their knowledge and consent. A legal review accessible at PMC3440234 notes that while courts have in some cases held that separated biological material is not property in the traditional sense, this does not mean commercial use without disclosure is ethically or legally acceptable. In practice, consent documents often specify that the donor has no rights to profits from resulting commercial products, but that is different from the institution being permitted to pursue such products without any disclosure.
What does the FDA mean when it says adipose tissue is a structural tissue?
The FDA’s minimal manipulation and homologous use guidance classifies tissues as either structural or non-structural for purposes of applying the minimal manipulation standard. Adipose tissue falls in the structural category because its primary recognized biological functions are cushioning, support, and energy storage. For structural tissues, the minimal manipulation standard asks whether processing preserves the characteristics that make the tissue useful as a structural material. Enzymatic or aggressive mechanical processing that changes the tissue’s composition or architecture crosses into more than minimal manipulation.
Why does isolating cells from fat with enzymes often count as more than minimal manipulation?
Enzymatic digestion breaks apart the extracellular matrix that holds adipose tissue together, removes the adipocyte majority of the tissue, and produces a concentrated cell population that is compositionally very different from the original fat tissue. The FDA’s position, consistent across its guidance documents and upheld in federal court, is that this process alters the original relevant characteristics of adipose tissue in a way that goes beyond preparation for storage or transfer. The resulting SVF is a different product from intact adipose tissue, and the FDA treats it as such for regulatory classification purposes.
What is FDA Expanded Access and how is it different from joining a clinical trial?
Expanded Access is a regulatory pathway allowing patients with serious or life-threatening conditions to access investigational products outside of clinical trials when no comparable alternative exists and the potential benefit justifies the risk. It requires manufacturer cooperation, physician application to the FDA, and FDA authorization. A clinical trial is a formal research study with defined protocols, randomization where applicable, IRB oversight, and data collection intended to establish safety and efficacy. The Reagan-Udall Expanded Access Navigator is a free resource that explains both pathways and helps patients identify whether any specific program exists for a product they are interested in.
What does Florida’s 2025 stem cell therapy law require doctors to tell patients?
Florida SB 1768 requires physicians offering non-FDA-approved stem cell therapies to obtain a signed informed consent form before performing the procedure. The consent must disclose that the therapy is not FDA-approved, describe recognized risks and complications, describe anticipated results and potential benefits, and explain alternatives including the option of no treatment. Physicians must also encourage patients to consult their primary care provider. Advertising for these therapies must include a clearly visible notice of non-FDA-approved status. The enrolled bill text is available at the Florida Senate.
How can I tell if a “stem cell freedom” or “own your cells” marketing claim is aligned with ethics and law?
Look for whether the marketing is accompanied by a specific, detailed consent form that covers ownership, commercial use, FDA status, and risks. Look for whether the clinic or bank can provide an IND number, IRB documentation, or ClinicalTrials.gov registration for any therapy they describe as research. Ask whether the facility has an FDA tissue establishment registration number that can be independently verified. Marketing language about freedom and ownership that is not backed by contract provisions covering those specific terms should be treated as aspirational rather than contractual.
Where can I find more information on tissue ownership, commercial use, and biobank ethics?
The primary sources cited in this article are all publicly accessible. The AMA Code of Medical Ethics opinion on commercial use of biological materials is available at ama-assn.org. The review of ethical and legal considerations in tissue ownership is at PMC3440234. The adipose stem cell bank ethics analysis is at PubMed. The FDA guidance on minimal manipulation and homologous use is at fda.gov. The Reagan-Udall Navigator is at navigator.reaganudall.org. Florida SB 1768 is at the Florida Senate website.
Key Takeaways for Patients Considering Banking or Treatment
Patients who bank tissue or pursue stem cell therapies are usually trying to protect their health or preserve options for the future. They are not approaching these decisions as legal exercises. But the legal and ethical dimensions of these decisions are real and have real consequences, and understanding them is one of the practical things that separates an informed patient from one who only read the marketing.
Save My Fat’s aim is to make the legal, ethical, and regulatory side of adipose tissue banking and stem cell therapy as transparent and understandable as the science.
The practical framework:
- Ownership, use rights, and any profit-sharing arrangements are defined by contracts and consent forms, not by marketing language or assumptions. Read the specific contract provisions before signing.
- Ethical and legal guidance from the AMA and biobank ethics literature requires clear disclosure when tissues may be used commercially and when therapies are not FDA-approved.
- The FDA treats many adipose-derived products as drugs or biologics when they are more than minimally manipulated or used for non-homologous purposes. State laws that authorize unapproved therapies do not change federal product classification.
- Expanded Access is a specific, regulated pathway for serious or life-threatening conditions; it is not a general permission to offer investigational products commercially.
- Banking adipose tissue preserves a biological option within a defined regulatory framework. It does not guarantee future therapies, create automatic rights to downstream products, or produce financial returns unless a contract explicitly provides for those things.
Patients are encouraged to bring this article to their clinicians and, where appropriate, legal counsel before signing any banking agreement or stem cell therapy consent. The patient’s guide to ADSCs, the adipose tissue banking guide, and the information on family banking are the places to connect these legal and ethical issues with the underlying biology and service structure. The about page describes who Save My Fat is and the standards it holds itself to.
This article is for educational purposes only and does not constitute legal or medical advice. Legal review and medical review including health law and regulatory affairs input is required before publication. Patients must consult their own lawyers and licensed clinicians before signing any tissue banking or stem cell therapy agreement.
Last Updated: April 25, 2026
